According to Bairen Medical's announcement, the company's self-developed transcatheter pulmonary valve system was approved and registered by the State Drug Administration. It is the company's third interventional valve product approved through a special review procedure for innovative medical devices. It is a “13th Five-Year Plan” national key research and development plan project of the Ministry of Science and Technology. It can meet the needs of all patients with transcatheter pulmonary valve replacement and achieve the same durability as surgical biological valves. There is uncertainty about the actual sales situation of this product after launch, and it is not possible to predict the impact on the company's future revenue.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.